



NOTICE TO THE ANNUAL GENERAL MEETING OF REDSENSE MEDICAL AB (PUBL)

Redsense Medical AB (publ) will hold its Annual General Meeting on Wednesday, May 20, 2026 at 16.30 at Profilhotels Halmstad Plaza, Anna Lindhs Plats, 302 66 Halmstad. Registration takes place from 16.00. Before the Annual General Meeting, light refreshments will be served and the company's products will be displayed.

RIGHT TO PARTICIPATE AND NOTIFICATION TO THE COMPANY

Anyone wishing to attend the meeting must:

- i. be registered as a shareholder in the share register kept by Euroclear Sweden AB on Monday, May 11, 2026; and
- ii. notify the company of their intention to participate no later than Thursday, May 13, 2026

Notification of attendance shall be made by e-mail to info@redsensemecial.com or in writing to the company at the address Redsense Medical AB, Storgatan 36, 302 43 Halmstad. When giving notice of attendance, please state your name or company name, personal identification number or organization number, address and daytime telephone number. For notification of assistants, the notification procedure applies as above.

NOMINEE REGISTERED SHARES

Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to participate in the Meeting, have their shares registered in their own name through a nominee, so that they are registered in the share register kept by Euroclear Sweden AB on Monday, May 11, 2026. Such registration may be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the nominee's procedures in such time in advance as the nominee determines. Voting rights registrations made by the relevant nominee no later than Thursday, May 13, 2026 will be taken into account in the preparation of the share register.

PROXY AND PROXY FORMS

Anyone who is not present in person at the meeting may exercise their rights at the meeting by proxy with a written, signed and dated power of attorney. Forms of proxy are available on the company's website, www.redsensemecial.com. The form of proxy can also be obtained from the company at the above address. If the power of attorney is issued by a legal entity, a copy of the registration certificate or equivalent authorization document for the legal entity must be attached. The power of attorney may not be older than one year unless a longer period of validity is specified in the power of attorney, but no longer than five years. To facilitate entry to the meeting, forms of proxy, registration certificates and other authorization documents should be received by the company well in advance of the meeting.

PROPOSED AGENDA

1. Opening of the meeting
2. Election of the Chairman of the General Meeting
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Election of one or two persons to verify the minutes
6. Examination of whether the meeting has been duly convened
7. Presentation of the annual report and auditor's report
8. Resolution
 - a. on the adoption of the annual accounts;
 - b. on the appropriation of the result according to the adopted balance sheet ; and
 - c. on the discharge from liability of the members of the Board of Directors and the CEO
9. Resolution on the number of members and deputy members of the Board of Directors and the number of auditors and deputy auditors
10. Resolution on the remuneration of the Board of Directors and auditors
11. Election of the board of directors and auditors and any deputy board members and deputy auditors
12. Resolution on authorization to issue shares
13. Closing of the meeting

PROPOSAL FOR A DECISION

Election of the Chairman of the General Meeting (item 2)

The Nomination Committee proposes that Susanne Olauson or, in her absence, the person designated by the Board of Directors be appointed Chairman of the Meeting.

Resolution on the appropriation of profits according to the adopted balance sheet (item 8.b)

The Board proposes that the distributable profit be allocated so that SEK 32,043,031 are carried forward to the new account.

Resolution on determination of the number of members and deputy members of the Board of Directors and the number of auditors and deputy auditors; resolution on determination of fees to the Board of Directors and auditors; election of the Board of Directors and auditors and any deputy members and deputy auditors (items 9 -11)

The company's nomination committee proposes the following:

Item 9: That the Board of Directors, for the period until the end of the next Annual General Meeting, shall consist of five Board members elected by the General Meeting without deputies, and that the company shall have one auditor without deputy for the period until the end of the next Annual General Meeting.

Item 10: That board fees, for the period until the end of the next annual general meeting, shall be paid with SEK 250,000 for the chairman of the board and with SEK 125,000 each to other board members who do not receive a salary from the company, and that fees to the auditor shall be paid according to current approved invoice.

Item 11: To re-elect Susanne Olauson, Johannes Köpple, Mike Griffiths and Martin Roos and to elect Michael Kraus as members of the Board of Directors for the period until the end of the next Annual General Meeting. The Nomination Committee proposes the re-election of Susanne Olauson as Chairman of the Board for the period until the end of the next Annual General Meeting.

Michael A. Kraus: Michael is a nephrologist with 35 years of experience. He trained at the University of Iowa and later held faculty positions there as well as at Indiana University. He served at Indiana University for 25 years, rising to the rank of Clinical Professor and Clinical Chief. Michael later joined the dialysis industry as Associate Chief Medical Officer at NxStage Medical and Fresenius Kidney Care. Dr.

Kraus is a recognized leader in CRRT, home dialysis, and ESKD care, with extensive experience in patient care, administration, and government relations. He has authored numerous manuscripts and book chapters and is an internationally recognized speaker.

Information on the proposed Board members is available on the company's website, www.redsensemedical.com.

The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of the registered accounting firm Azets Revision och Rådgivning AB, reg. no. 559480-5169, ("**Azets**") with the authorized public accountant Andreas Johansson as auditor in charge.

Resolution on authorization to issue shares (item 12)

The Board of Directors proposes that, for the period until the next Annual General Meeting, the Board of Directors be authorized to, on one or more occasions and with or without deviation from the shareholders' preferential rights, resolve on new issues of shares, issue of warrants and/or issue of convertible bonds. Decisions to issue shares by virtue of the authorization may not exceed the total number of shares - including the number of shares issued, the exercise of warrants, and/or the conversion of convertibles - corresponding to 20 percent of the total number of outstanding shares in the company at the time the authorization is exercised for the first time. The foregoing shall not be understood to prevent warrants and/or convertible bonds from being subject to recalculation terms which, if applied, may result in a different number of shares.

The authorization shall include the right for the Board of Directors to decide on an issue with cash payment, payment in kind or payment by way of set-off and otherwise be subject to conditions referred to in Chapter 2, Section 5, second paragraph, 1-3 and 5 of the Swedish Companies Act. 5, second paragraph 1-3 and 5 of the Companies Act.

SPECIAL MAJORITY REQUIREMENTS

For a valid resolution under item 12, the proposal must be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.

DOCUMENTS

Complete proposals, accounting documents and the auditor's report for 2025 will be available at the company and on the company's website www.redsensemedical.com no later than three weeks before the meeting and will be sent immediately and free of charge to shareholders who so request and state their postal address. The documents will also be available at the meeting.

INFORMATION AT THE MEETING

Shareholders are reminded of their right to request information from the Board of Directors and the Managing Director at the Meeting in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

PROCESSING OF PERSONAL DATA

For information on how your personal data is processed, please see: <https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf>.

Halmstad in April 2026

Redsense Medical AB (publ)

The Board of Directors

Contact information

For more information, please contact:
Sebastien Bollue, CEO

Telephone: +46 72-171 1264

E-mail: [sebastien.bollue \(at\) redsensemedical.com](mailto:sebastien.bollue@redsensemedical.com)

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS)